-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $158

Benzinga·05/06/2026 23:11:44
Listen to the news
Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $171 to $158.